Search research articles
Contact Us
Filters
Showing results (191-200 of 242) with videos related to
Page
of 25
Sort By:
The Lancet. Oncology
|
June 18, 2016
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
Koichi Goto, Yuichiro Ohe, Taro Shibata, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
Keunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, et al.
The Lancet. Oncology
|
November 3, 2015
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
Takehito Shukuya, Takeharu Yamanaka, Takashi Seto, et al.
British Journal of Cancer
|
September 13, 2018
A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L
Tomonari Sasaki, Takashi Seto, Takeharu Yamanaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2006
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301
Sayaka Onoda, Noriyuki Masuda, Takashi Seto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2019
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)
Takashi Seto, Koichi Azuma, Takeharu Yamanaka, et al.
The Lancet. Respiratory Medicine
|
January 20, 2020
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
Daniel S-W Tan, Natasha B Leighl, Gregory J Riely, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 17, 2010
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study
Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita, et al.
JTO Clinical and Research Reports
|
June 3, 2025
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC: RELAY Japanese Subset
Makoto Nishio, Takashi Seto, Martin Reck, et al.
Clinical Lung Cancer
|
June 12, 2018
Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301)
Shinji Atagi, Junki Mizusawa, Satoshi Ishikura, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 242) with videos related to
Sort By:
Page
of 25
The Lancet. Oncology
|
June 18, 2016
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
Koichi Goto, Yuichiro Ohe, Taro Shibata, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
Keunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, et al.
The Lancet. Oncology
|
November 3, 2015
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial
Takehito Shukuya, Takeharu Yamanaka, Takashi Seto, et al.
British Journal of Cancer
|
September 13, 2018
A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L
Tomonari Sasaki, Takashi Seto, Takeharu Yamanaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2006
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301
Sayaka Onoda, Noriyuki Masuda, Takashi Seto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2019
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)
Takashi Seto, Koichi Azuma, Takeharu Yamanaka, et al.
The Lancet. Respiratory Medicine
|
January 20, 2020
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
Daniel S-W Tan, Natasha B Leighl, Gregory J Riely, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 17, 2010
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study
Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita, et al.
JTO Clinical and Research Reports
|
June 3, 2025
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC: RELAY Japanese Subset
Makoto Nishio, Takashi Seto, Martin Reck, et al.
Clinical Lung Cancer
|
June 12, 2018
Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301)
Shinji Atagi, Junki Mizusawa, Satoshi Ishikura, et al.
Page
of 25